Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer.

@article{Yamashita2008LowPO,
  title={Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer.},
  author={Hiroko Yamashita and Mariko Nishio and Tatsuya Toyama and Hiroshi Sugiura and Naoto Kondo and Shunzo Kobayashi and Yoshitaka Fujii and Hirotaka Iwase},
  journal={Endocrine-related cancer},
  year={2008},
  volume={15 3},
  pages={755-63}
}
Endocrine therapy has become the most important treatment option for women with estrogen receptor (ER)-positive breast cancer. Urgently needed are prognostic assays that can identify those who need additional adjuvant therapy, such as signal transduction inhibitors or chemotherapy, for ER-positive early breast cancer. We examined phosphorylation of ERalpha serine (Ser) 118, ERalpha Ser167, p44/42 mitogen-activated protein kinase (MAPK), and Akt and expression of progesterone receptor, amplified… CONTINUE READING
50 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

Similar Papers

Loading similar papers…